Twist Bioscience Narrows Q1 Net Loss to $30.5M as Operating Expenses Shift
Twist Bioscience Corporation, a synthetic biology company that engineers DNA synthesis platforms, reported a net loss of $30.5 million for the quarter ending December 31, 2025, a 3.4% improvement from the $31.6 million loss in the same quarter last year.
Twist Bioscience Corporation (NASDAQ: TWST), a synthetic biology company that engineers DNA synthesis platforms, reported a net loss of $30.5 million for the quarter ending December 31, 2025, down from a $31.6 million loss in the same quarter last year. The loss per share came in at $0.50, compared to $0.53 a year earlier. Read more earnings reports.
The company's operating loss improved to $32.9 million from $34.6 million in the prior-year quarter. Cost of revenue rose 8.4% to $49.7 million from $45.9 million, while the company sharply reduced research and development spending by 19.6% to $17.1 million from $21.3 million. Selling, general and administrative expenses, however, jumped 24.1% to $69.7 million from $56.2 million.
Cash and cash equivalents stood at $148.6 million as of December 31, 2025, down from $183.0 million at the end of the prior quarter. The company burned through $24.8 million in operating cash during the quarter, compared to $21.4 million in the year-ago period. Investing activities consumed an additional $9.9 million, primarily for capital expenditures.
Total assets declined slightly to $638.1 million from $641.9 million at the end of the prior quarter. Current assets fell to $303.9 million from $333.0 million, driven by the drop in cash and a decrease in accounts receivable to $50.1 million from $57.0 million. Inventory increased to $32.9 million from $28.3 million.
The company's stockholders' equity decreased to $456.1 million from $473.0 million at September 30, 2025. Total liabilities rose to $182.0 million from $168.9 million, though current liabilities fell to $80.4 million from $91.4 million. Common shares outstanding increased to 61.3 million from 60.6 million during the quarter.
Financial Summary
| Metric | Q1 FY2026 | Q1 FY2025 | Change |
|---|---|---|---|
| Net Loss | $30.5M | $31.6M | -3.4% |
| Operating Loss | $32.9M | $34.6M | -5.0% |
| Cost of Revenue | $49.7M | $45.9M | +8.4% |
| R&D Expenses | $17.1M | $21.3M | -19.6% |
| SG&A Expenses | $69.7M | $56.2M | +24.1% |
| Operating Cash Flow | ($24.8M) | ($21.4M) | -15.8% |
| Cash Position | $148.6M | $183.0M* | -18.8% |
| EPS (Diluted) | ($0.50) | ($0.53) | +5.7% |
*Prior quarter comparison (September 30, 2025)